Abstract
Liver biopsy remains the diagnostic gold standard for assessing liver fibrosis severity; however, its cost and invasiveness highlight the need for accurate, noninvasive alternatives. This study evaluates the performance of FibroPredict, a novel algorithm, for detecting advanced liver fibrosis in high-risk populations. It compares its accuracy to transient elastography (TE), the current noninvasive reference standard. A retrospective cohort study of 316 high-risk individuals used electronic health record (EHR) data and routine laboratory results to calculate FibroPredict, APRI (Aspartate Aminotransferase-to-Platelet Ratio Index), and FIB-4 scores, which were then compared to liver stiffness measurements (LSM) obtained through TE. FibroPredict demonstrated a sensitivity of 96.8% and a negative predictive value (NPV) of 90.9% at a cutoff score of ≥135 for detecting advanced fibrosis (LSM ≥ 8 kPa), outperforming FIB-4 in sensitivity and the ability to rule out advanced fibrosis. APRI, at a cutoff of 1.5, showed high specificity (98.41%) but low sensitivity (6.32%), making it more suitable for confirming rather than excluding advanced fibrosis. However, FibroPredict’s specificity was low (21.0%), resulting in higher false-positive rates. FIB-4, with a cutoff of ≥2.67, showed lower sensitivity but better specificity (46.8%). FibroPredict’s excellent sensitivity and high NPV make it a promising tool for ruling out advanced fibrosis, particularly in resource-limited settings. However, its low specificity underscores the need for confirmatory tests, such as TE, or combining it with APRI to enhance diagnostic accuracy.
Get full access to this article
View all access options for this article.